478 related articles for article (PubMed ID: 19504731)
1. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
[TBL] [Abstract][Full Text] [Related]
2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
3. Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.
Bunupuradah T; Puthanakit T; Fahey P; Kariminia A; Yusoff NK; Khanh TH; Sohn AH; Chokephaibulkit K; Lumbiganon P; Hansudewechakul R; Razali K; Kurniati N; Huy BV; Sudjaritruk T; Kumarasamy N; Fong SM; Saphonn V; Ananworanich J;
Antivir Ther; 2013; 18(4):591-8. PubMed ID: 23296119
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
[TBL] [Abstract][Full Text] [Related]
7. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.
Musiime V; Ssali F; Kayiwa J; Namala W; Kizito H; Kityo C; Mugyenyi P
AIDS Res Hum Retroviruses; 2009 Oct; 25(10):989-96. PubMed ID: 19778270
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment.
Wattanutchariya N; Sirisanthana V; Oberdorfer P
HIV Med; 2013 Apr; 14(4):226-32. PubMed ID: 23094820
[TBL] [Abstract][Full Text] [Related]
10. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
11. Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Jittamala P; Puthanakit T; Chaiinseeard S; Sirisanthana V
Pediatr Infect Dis J; 2009 Sep; 28(9):826-30. PubMed ID: 19654564
[TBL] [Abstract][Full Text] [Related]
12. Risk of first-line antiretroviral therapy failure in HIV-infected Thai children and adolescents.
Bunupuradah T; Sricharoenchai S; Hansudewechakul R; Klinbuayaem V; Teeraananchai S; Wittawatmongkol O; Akarathum N; Prasithsirikul W; Ananworanich J;
Pediatr Infect Dis J; 2015 Mar; 34(3):e58-62. PubMed ID: 25478649
[TBL] [Abstract][Full Text] [Related]
13. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
[TBL] [Abstract][Full Text] [Related]
16. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
[TBL] [Abstract][Full Text] [Related]
17. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
[TBL] [Abstract][Full Text] [Related]
19. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
20. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
